Adjustment Dosage of Digoxin in Heart Failure Patients at Margono Soekardjo Hospital Purwokerto

  • Masita Wulandari Suryoputri Universitas Jenderal Soedirman
  • Laksmi Maharani Universitas Jenderal Soedirman
  • Ika Mustikaningtias Universitas Jenderal Soedirman
DOI: https://doi.org/10.35814/jifi.v19i2.778

Abstract

Due to the high prevalence of heart failure in Indonesia causes the use of digoxin is increasing. The drug level in blood needs to be monitored because digoxin is a narrow therapeutic index drug. It is necessary to adjust the dose in the patient, so that clinical outcomes are achieve and toxic effects can be avoided if the estimated drug levels in the blood do not match the therapeutic range. The maintenance dose of oral digoxin is 0.0625 - 0.125 mg / day for heart failure patients and it is expected that the therapeutic range of digoxin in the blood range from 0.5 to 0.9 ng / ml. The purpose of this study was to determine the estimation of digoxin levels in blood in patients with heart failure and the calculation of dosage adjustments using a pharmacokinetic approach so that blood levels of drugs ware in the therapeutic range. This research employs a quantitative observational method conducted prospectively by using a total sampling technique. The results showed that the digoxin level of 4 patients (13,33%) were in the range of therapeutic range (0,50 – 0,90 ng/ml) and 26 patients (86,67%) exceed the therapeutic range (>1,00 ng/ml). Digoxin dose adjustment was made in 26 patients (86,67%) individually with an interval of every 24 hours in order to achieve Css according to the therapeutic range. Based on the results it can be concluded that in heart failure patients who have blood digoxin levels exceed the therapeutic range need dose adjustments to improve clinical outcomes and prevent toxicity in patients.

References

1. Kemenkes RI. Riset Kesehatan Dasar ; RISKESDAS. Jakarta : Balitbang. 2018.

2. Virgadamo, S., Charnigo, R., Darrat, Y., Moreles, G., Elayi, C.S. Digoxin : A Systematic Review in Atrial Fibrilation, Congestive Heart Failure and Post Myocardial Infraction. World Journal of Cardiology. 2015;7(11):808-16. Doi : 10.4330/wjc.v7.i11.808

3. Nugroho, A.E. Jakarta: EGC; 2012. Hal 26-30. Farmakologi : Obat - Obat Penting dalam Pembelajaran Ilmu Farmasi dan Dunia Kesehatan.

4. Bajraktarević, A Safety and Efficacy of Digoxin Therapy—Where Are We Now?. Journal of Pharmacy and Pharmacology,. 2016.4(3):128–134. Doi : 10.17265/2328-2150/2016.03.004

5. Adams KF Jr., et al. Clinical benefit of low serum digoxin concentration in heart failure. J Am Coll Cardiol. 2002.39:946-953. Doi : 10.1016/s0735-1097(02)01708-4.

6. Nogue, S., Cino, J., Civeira, E., Puiguriguer, J., Putze, G.B., Dueñas, A., Soy, D., Aguilar, R., Corominas, N. Digitalis Poisoning : The Basis for Treatment with Antidigoxin Antibodies. Emergencias. 2012.24(6):462-75.

7. Limon, G., Ersoy, G., Oray, N.C., Bayram, B., Limon, O. Retrospective evaluation of patients with elevated digoxin levels at an emergency department. Turkish Journal of Emergency Medicine. 2015.16(1): 17-21. Doi : 1.1016/j.tem.2015.10.001

8. Wahyono, D. Farmakokinetika Klinik. Yogyakarta : Gadjah Mada University Press. 2013. p. 12-13, 20-1.

9. Mosadegh, M.M., Bafghi, S.M.S. Digoxin Compliance: A Pharmacokinetic Quantification, Medical Journal of Islamic Academy of Sciences. 2001.14(3): 117-22

10. Scappaticci, G.B., Regal, R.E. Cockcroft-Gault Revisited: New Deliverance On Recommendations For Use In Cirrhosis. World J Hepatol. 2017.9(3):131-8. Doi: 10.4254/wjh.v9.i3.131.

11. Sayed, Y.M.E. Predictive performance of four pharmacokinetic methods for calculating digoxin dosage. Journal of Clinical Pharmacy and Therapeutics. 1995.20(5):297–304. Doi : 10.1111/j.1365-2710.1995.tb00665.x

12. Benlmouden, A., Billaud, E.M. Evidence Based Digoxin Therapeutic Monitoring A Lower and Narrower Therapeutic Range. 2016.3(1):3–6.

13. Maury, P., Rollin, A., Galinier, A., Juillière, Y. Role of Digoxin in Controlling the Ventricular Rate During Atrial Fibrillation: A Systematic Review and A Rethinking, Research Reports in Clinical Cardiology. 2014.5: 93-101. Doi : 10.2147/RRCC.S44919.

14. Pincus, M. Management of digoxin toxicity. Australian Prescriber, 2016;39(1):18–20. Doi : 10.18773/austpresce.2016.006

15. Oncu, S., Gelal, A., Aslan, O., & Ucku, R.S. Appropriateness of digoxin measurement in hospitalized patients, Biochem Med (Zagreb). 2018.28(1): 1 - 5. Doi : 10.11613/BM.2018.010901

16. Ragab, M. dan Solihat, M.F. Clinical utility of serum digoxin level in cardiac patients for Diagnosis of Chronic Digitalis Toxicity. Journal of Clinical toxicology. 2012. 2(10): 1-5. Doi: 10.4172/2161-0495.1000150.

17. PERKI. Pedoman Tatalaksana Gagal Jantung Edisi Pertama. Buku Pedoman Tatalaksana Gagal Jantung, Edisi Pertama. 2015.p. 14–27.

18. Covis. LANOXIN Injection. Jubilant HollisterStier General Partnership Kirkland. Canada : Pharmaceuticals. Inc. 2015.
Published
2021-10-31
How to Cite
SURYOPUTRI, Masita Wulandari; MAHARANI, Laksmi; MUSTIKANINGTIAS, Ika. Adjustment Dosage of Digoxin in Heart Failure Patients at Margono Soekardjo Hospital Purwokerto. JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 19, n. 2, p. 248-253, oct. 2021. ISSN 2614-6495. Available at: <http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/778>. Date accessed: 31 dec. 2024. doi: https://doi.org/10.35814/jifi.v19i2.778.
Citation Formats
Issue
Vol 19 No 2 (2021): JIFI
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.